Adaptive Biotechnologies soars 8.5% as MRD business achieves profitability

Adaptive Biotechnologies (ADPT) shares surged 8.5% after reporting second-quarter results that significantly exceeded analyst expectations, driven by robust performance in its Minimal Residual Disease (MRD) business. The company posted revenue of $58.9 million, a 36% year-over-year increase, and notably achieved profitability in its core MRD segment with $1.9 million in Adjusted EBITDA. Following this strong quarter, Adaptive raised its full-year 2025 MRD revenue guidance to $190-$200 million and reduced its projected cash burn, signaling an improved financial outlook and growth trajectory.

Analysis

Adaptive Biotechnologies (ADPT) reported a robust second quarter, significantly outperforming analyst expectations and signaling a pivotal operational inflection point. The company's revenue grew 36% year-over-year to $58.9 million, substantially exceeding the $49.4 million consensus estimate. This performance was driven by the Minimal Residual Disease (MRD) business, which saw a 42% YoY revenue increase and now accounts for 85% of total revenue. Critically, the MRD segment achieved profitability this quarter with an Adjusted EBITDA of $1.9 million, a major milestone supporting the company's path to sustainable earnings. This top-line strength is underpinned by a 37% YoY growth in clonoSEQ test volumes. Management's confidence is reflected in the raised full-year 2025 MRD revenue guidance to a range of $190-$200 million. Furthermore, the company demonstrated improved financial discipline by reducing total operating expenses by 7% YoY to $83.9 million and lowering its projected full-year cash burn to between $45 million and $55 million, all while maintaining a healthy cash position of $222 million.

Key Decisions for Investors

• The significant earnings beat, achievement of profitability in the core MRD segment, and upwardly revised revenue guidance suggest a strong operational inflection point that may warrant a bullish outlook on the stock.
• Investors should note the improved capital discipline, evidenced by a 7% year-over-year reduction in operating expenses and a lower full-year cash burn forecast, which strengthens the company's financial stability and extends its operational runway.
• The ongoing integration of clonoSEQ into major EMR platforms like Flatiron’s OncoEMR should be monitored as a key catalyst for accelerating test volume adoption and solidifying market leadership.